These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 28580808)

  • 1. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
    Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
    Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
    Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib: a promising treatment for hepatocellular carcinoma.
    Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
    Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
    [No Abstract]   [Full Text] [Related]  

  • 9. Regorafenib for the treatment of hepatocellular carcinoma.
    Tovoli F; Granito A; De Lorenzo S; Bolondi L
    Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 14. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
    Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
    J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
    Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Ishikawa T; Nakano I; Hirooka Y; Goto H
    Oncology; 2018; 95(2):91-99. PubMed ID: 29723866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
    Personeni N; Pressiani T; Rimassa L
    Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib Approved for Liver Cancer.
    Cancer Discov; 2017 Jul; 7(7):660. PubMed ID: 28522682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
    Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
    Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.